COMMON STOCK PURCHASE WARRANT ASPIRA WOMEN’S HEALTH Inc.Aspira Women's Health Inc. • July 2nd, 2024 • In vitro & in vivo diagnostic substances
Company FiledJuly 2nd, 2024 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, beginning on the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the three (3) year anniversary of the Initial Exercise Date (the “Termination Date”), but not thereafter, to subscribe for and purchase from Aspira Women’s Health Inc., a Delaware corporation (the “Company”), up to ______ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2024 • Aspira Women's Health Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 2nd, 2024 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2024 (the “Effective Date”), between Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).